Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.61 |
| ▸ | NOS3 | P29474 | 2/20 | 0.61 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057615 | 0.76 | NOS2 (1.00) | NOS2NOS3DRD2DRD3ADRA2A | |
| SCHEMBL20645736 | 0.76 | NOS2 (0.56) | NOS2NOS3NISCHDRD2DRD3 | |
| SCHEMBL22978809 | 0.73 | NOS2 (0.62) | NOS2NOS3NISCHDRD2DRD3 | |
| SCHEMBL3307581 | 0.73 | NOS2 (0.53) | NOS2NOS3NISCHDRD2DRD3 | |
| SCHEMBL2980218 | 0.71 | NOS3 (0.54) | NOS2NOS3GRIN2BMAOAACHE | |
| SCHEMBL15763737 | 0.70 | NOS3 (0.52) | NOS2NOS3DRD2DRD3HTR1A | |
| SCHEMBL1870494 | 0.69 | NOS2 (0.60) | NOS2NOS3NISCHDRD2DRD3 | |
| SCHEMBL8172900 | 0.68 | NOS3 (0.46) | NOS2NOS3DRD2DRD3GRIN2B | |
| SCHEMBL14498861 | 0.67 | NOS3 (0.41) | NOS2NOS3NISCHDRD2DRD3 | |
| SCHEMBL8200277 | 0.65 | NOS3 (0.47) | NOS2NOS3DRD2DRD3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916195-A | Therapeutic agents and uses thereof | 安科生命科学有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2008135526-A1 | CARBOXYLIC ACID AMIDES AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | NOS2 809/4885NOS3 1683/4885NISCH 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.